Literature DB >> 30882962

Modulatory effects of cannabinoids on brain neurotransmission.

Koby Cohen1, Abraham Weizman2, Aviv Weinstein1.   

Abstract

Recreational and chronic cannabis use has been associated with a range of acute and chronic effects including; anti-nociceptive actions, anxiety, depression, psychotic symptoms and neurocognitive impairments. The mechanisms underlying cannabinoid-based drugs effects are not fully known but given the neuro-modulatory functions of the endocannabinoid system, it seems likely that agonistic activity at the cannabinoid type-1 receptors (CB1 ) might modulate the functions of other neurotransmitter systems. The present review has summarized the currently available pre-clinical and clinical data on the interactions of CB1 and cannabinoid type-2 receptors (CB2 ) with the central neurotransmitters; dopamine, serotonin, noradrenaline, GABA, glutamate and opioids. Acute and chronic exposures to cannabinoids exert pharmacological alterations in the mammalian brain that have profound implications for our understanding of the neuropharmacology of cannabinoid-based drugs and their effects on mental health and the brain. A recent emergence uses of cannabis for medical purpose together with legalization and decriminalization of cannabis and increasing use of highly potent synthetic cannabinoids raise a growing concern over the effects of cannabinoids and their interaction with other neurotransmitters on physical and mental health.
© 2019 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  GABA; cannabinoids; dopamine; glutamate; opioids; serotonin

Year:  2019        PMID: 30882962     DOI: 10.1111/ejn.14407

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  22 in total

1.  How lactate links cannabis to social behaviour.

Authors:  Pierre J Magistretti
Journal:  Nature       Date:  2020-07       Impact factor: 49.962

2.  Effects of GABAA receptors in nucleus cuneiformis on the cannabinoid antinociception using the formalin test.

Authors:  Junjie Chen; Parisa Hasanein; Alireza Komaki; Siamak Yari
Journal:  Psychopharmacology (Berl)       Date:  2021-03-13       Impact factor: 4.530

3.  Cannabis and Depression.

Authors:  Daniel Feingold; Aviv Weinstein
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Progress on the application of positron emission tomography imaging of cannabinoid type 1 receptor in neuropsychiatric diseases.

Authors:  Lijuan Ma; Shuang Wu; Kai Zhang; Mei Tian; Hong Zhang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-10-25

5.  The effect of URB597, exercise or their combination on the performance of 6-OHDA mouse model of Parkinson disease in the elevated plus maze, tail suspension test and step-down task.

Authors:  Mohaddeseh Ebrahimi-Ghiri; Faezeh Shahini; Mohammad-Reza Zarrindast
Journal:  Metab Brain Dis       Date:  2021-10-02       Impact factor: 3.584

6.  Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders.

Authors:  James J Prisciandaro; William Mellick; Lindsay M Squeglia; Sara Hix; Lauren Arnold; Bryan K Tolliver
Journal:  Addict Biol       Date:  2021-08-14       Impact factor: 4.093

7.  Addiction in focus: molecular mechanisms, model systems, circuit maps, risk prediction and the quest for effective interventions.

Authors:  Rita Z Goldstein; Michel Barrot; Barry J Everitt; John J Foxe
Journal:  Eur J Neurosci       Date:  2019-08       Impact factor: 3.386

8.  Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study.

Authors:  Reilly R Kayser; Margaret Haney; Marissa Raskin; Caroline Arout; Helen Blair Simpson
Journal:  Depress Anxiety       Date:  2020-05-07       Impact factor: 6.505

Review 9.  Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway.

Authors:  Alexandre Vallée; Yves Lecarpentier; Jean-Noël Vallée
Journal:  Mol Psychiatry       Date:  2021-04-09       Impact factor: 15.992

Review 10.  Down and High: Reflections Regarding Depression and Cannabis.

Authors:  Catherine Langlois; Stéphane Potvin; Atul Khullar; Smadar Valérie Tourjman
Journal:  Front Psychiatry       Date:  2021-05-14       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.